|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | LUX-Lung 3: A randomized, open-label, phase m study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations显示文摘 | Yang J Schuler MH Yamamoto N | 2012 | J Clin Oncol2012，，： | 1 |
| 2 | A random- ized, open-label, phase Ⅲ study of afatinib versus pemetrexed and cispl- atin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations 显示文摘 | James-Chih-Hsin Y Schuler MH Nobuyuki-Yamamoto EA | 2012 | J Clin Oncol2012，30，： | 1 |
| 3 | LUX-lung 3:A randomized,open-label,phase Ⅲ study of afatinib vs pemetrexed and cisplatin as first line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations显示文摘 | Schuler MH Yamamoto N John K | 2012 | J Clin Oncol2012，30，： | 1 |
| 4 | Continuation ofafatinib beyond progression : Results of a randomized,open-label, phase HI trial of afatanib plus paclitaxel(P) versus investigator's choice chemotherapy ( CT) inpatients (pts) with metastatic nonsmall cell lung cancer(NSCLC ) progressed on erlotinib/gefitinib ( E/G) andafatanib LUX-Lung 5 (LL5) 显示文摘 | Schuler MH Yang CH Park K | 2014 | J Clin Oncol2014，32，15： | 1 |
| 5 | Overallsurvival ( OS) in patients ( pts) with advanced non-small cell lung cancer ( NSCLC) harboring common(Dell9/L858R) epidermal growth factor receptor muta-tions (EGFR mut) : Pooled analysis of two large open-label phase HI studies ( LUX-Lung 3 and LUX-Lung 6 ) comparing afatinib with chemotherapy(CT)显示文摘 | Yang JCH Sequist LV Schuler MH | 2014 | J Clin Oncol2014，32，15： | 1 |
| 6 | LUX-Lung 3: a randomized, open-label, phase Ⅲ study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations显示文摘 | Yang JC-H Schuler MH Yamamoto N | 2012 | J Clin Oncol 302012，7500，： | 1 |
| 7 | LUX-Lung 3: A ran-domized ,open-label,phase 瓜 study of afatinib versus peme-trexed and cisplatin as first-line treatment for patients with ad-vanced adenocarcinoma of the lung harboring EGFR-activatingmutations显示文摘 | Yang J Schuler MH Yamamoto N | 2012 | J Clin Oncol2012，30，： | 1 |
| 8 | Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC)harboring common (DeI19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase m studies (LUX-Lung 3 ILL3] and LUX-Lung 6 ) comparing Afatinib with chemotherapy (CT)显示文摘 | Yang JCH Sequist LV Schuler MH | 2014 | J Clin Oncol2014，32，15： | 1 |
| 9 | LUX-LUNG 3:a randomized,open-label,phase Ⅲ study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activation mutations显示文摘 | Yang JCH Schuler MH Yamamoto N | | 0，，： | 1 |
| 10 | Interim analysis of afa-tinib monotherapy in patients with metastatic NSCLC progressingafter chemotherapy and erlotinib/gefitinib( E/G) in a trial of afa-tinib plus paclitaxel versus investigator’s choice chemotherapy fol-lowing progression on afatinib monotherapy 显示文摘 | Schuler MH lanchard DP Yang J | 2012 | J Clin Oncol2012，，： | 1 |
| 11 | LUX-Lung 3:A randomized,open-label,phase Ⅲ study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung har- boring EGFR-activating mutations显示文摘 | Yang JC-H Schuler MH Yamamoto N | 2012 | J Clin Oncol2012，，： | 1 |
| 12 | LUX-Lung 3:A randomized,open-label,phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced ade-nocarcinoma of the lung harboring EGFR-activating mutations显示文摘 | Yang JCH Schuler MH Yamamoto N | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员